European Society of Cardiology

Congress 2018

SCROLL TO ARTICLES

Chairman and introduction
Marco de Carlo, Interventional Cardiologist, Pisa University Hospital, Pisa, Ital...
MOA of antithrombotics and risk factors
Robert Storey, Professor of Cardiology, University of Sheffield, and Consultant C...
Antithrombotic therapy in patients with asymptomatic PAD
Victor Aboyans, Professor of Medicine, Head of Department of Cardiology, Dupuytre...
Antithrombotic regimens in diabetic patients with PAD
Charalambos Vlachopoulos, Professor of Cardiology, University of Athens Medical S...

Risk factor control and unmet need in PAD cohorts
Marianne Brodmann, Professor of Internal Medicine, Head of the Clinical Division ...
Closing statement
Marco de Carlo

AIMS: Irbesartan slows rate of aortic root dilatation in Marfan syndrome

ARRIVE: No reduction in rate of first CV events with aspirin in moderate-risk patients

ASCEND: Reduced serious vascular events offset by increased bleeds with aspirin in individuals with diabetes

CAMELLIA-TIMI 61: Lorcaserin helps weight loss without CV adversity in overweight patients at high CV risk

COMMANDER HF: Rivaroxaban does not reduce deaths compared with placebo in chronic heart failure with reduced EF

COMPASS trial shows that GI or GU bleeds may signal cancer in patients with vascular disease treated with antithrombic therapy

The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.

Supported by